Clinicopathological characteristics of individuals with coexisting melanoma and chronic lymphocytic leukaemia: a multicentre cohort study.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
03
07
2022
pubmed:
9
7
2022
medline:
25
10
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
Individuals with a prior diagnosis of chronic lymphocytic leukaemia (CLL) have a higher risk of developing melanoma and exhibit poorer outcomes than patients without CLL. However, there are limited data reporting the clinicopathological features of melanoma diagnosed in patients with CLL. To review clinicopathological characteristics of patients with coexisting diagnoses of melanoma and CLL. A retrospective review was undertaken for patients with coexisting diagnoses of melanoma and CLL between 2005 and 2015 in 11 centres in the UK and Ireland. Overall, 46 cutaneous melanomas identified in 45 patients were included. In 28 (62.2%) patients, melanoma was diagnosed after an existing diagnosis of CLL. In this group, mean Breslow thickness was 2.7 mm (range 0.2-25 mm). Ten patients (35.7%) developed locoregional recurrence and 8 (28.6%) developed distant metastases. Melanoma-specific mortality was 5 of 28 (17.9%) and all-cause mortality was 13 of 28 (46.4%). In 17 patients, melanoma was diagnosed before CLL. In this group, mean BT was 2.9 mm (range 0.4-14 mm); five patients (29.4%) developed locoregional recurrence and three (17.6%) developed distant metastases. Melanoma-specific mortality was 1 of 17 (5.8%) and all-cause mortality was 5 of 17 (29.4%) in this group. To our knowledge, this is the first and largest cohort study to report clinicopathological data of coexisting melanoma and CLL in the UK and Ireland. Although the thickness of primary melanoma was not different before or after a CLL diagnosis, melanoma recurrence and melanoma-specific mortality appear to be more common in patients with a prior diagnosis of CLL.
Sections du résumé
BACKGROUND
BACKGROUND
Individuals with a prior diagnosis of chronic lymphocytic leukaemia (CLL) have a higher risk of developing melanoma and exhibit poorer outcomes than patients without CLL. However, there are limited data reporting the clinicopathological features of melanoma diagnosed in patients with CLL.
AIMS
OBJECTIVE
To review clinicopathological characteristics of patients with coexisting diagnoses of melanoma and CLL.
METHODS
METHODS
A retrospective review was undertaken for patients with coexisting diagnoses of melanoma and CLL between 2005 and 2015 in 11 centres in the UK and Ireland.
RESULTS
RESULTS
Overall, 46 cutaneous melanomas identified in 45 patients were included. In 28 (62.2%) patients, melanoma was diagnosed after an existing diagnosis of CLL. In this group, mean Breslow thickness was 2.7 mm (range 0.2-25 mm). Ten patients (35.7%) developed locoregional recurrence and 8 (28.6%) developed distant metastases. Melanoma-specific mortality was 5 of 28 (17.9%) and all-cause mortality was 13 of 28 (46.4%). In 17 patients, melanoma was diagnosed before CLL. In this group, mean BT was 2.9 mm (range 0.4-14 mm); five patients (29.4%) developed locoregional recurrence and three (17.6%) developed distant metastases. Melanoma-specific mortality was 1 of 17 (5.8%) and all-cause mortality was 5 of 17 (29.4%) in this group.
CONCLUSIONS
CONCLUSIONS
To our knowledge, this is the first and largest cohort study to report clinicopathological data of coexisting melanoma and CLL in the UK and Ireland. Although the thickness of primary melanoma was not different before or after a CLL diagnosis, melanoma recurrence and melanoma-specific mortality appear to be more common in patients with a prior diagnosis of CLL.
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1976-1981Informations de copyright
© 2022 British Association of Dermatologists.
Références
Brewer D, Habermann TM, Shanafelt TD. Lymphoma-associated skin cancer: incidence, natural history, and clinical management. Int J Dermatol 2013; 53: 267-74.
Farma JM, Zager JS, Barnica-Elvir V et al. A collision of diseases: chronic lymphocytic leukaemia discovered during lymph node biopsy for melanoma. Ann Surg Oncol 2012; 20: 1360-4.
Brewer JD, Shanafelt TD, Call TG et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukaemia. Int J Dermatol 2015; 54: e287-93.
Turk T, Saad AM, Al-Husseini MJ, Gad MM. The risk of melanoma in patients with chronic lymphocytic leukaemia; a population based study. Curr Probl Cancer 2020; 44: 100511.
Brewer JD, Shanafelt TD, Otley CC et al. Chronic lymphocytic leukaemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol 2012; 30: 843-9.
Famenini S, Martires KJ, Zhou H et al. Melanoma in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma. J Am Acad Dermatol 2015; 72: 78-84.
Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies. Melanoma Res 2016; 26: 188-94.
Levi F, Randimbison L, Te V-C, Vecchia CL. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996; 74: 1847-50.
McKenna DB, Doherty VR, McLaren KM, Hunter JA. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br J Dermatol 2000; 143: 171-3.
Wu PA, Stern RS, Huang V et al. Reduced-intensity conditioning regimens, prior chronic lymphocytic leukemia, and graft-versus-host disease are associated with higher rates of skin cancer after allogeneic hematopoietic stem cell transplantation. J Invest Dermatol 2019; 139: 591-9.
Mehrany K, Weenig RH, Pittelkow MR et al. High recurrence rates of basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukaemia. Arch Dermatol 2004; 140: 985-8.
Brewer JD, Shanafelt TD, Khezri F et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota. J Am Acad Dermatol 2015; 72: 302-9.
Mehrany K, Weenig R, Lee K et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukaemia. J Am Acad Dermatol 2005; 53: 1067-71.
Onajin O, Brewer J. Skin cancer in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2012; 10: 571-6.
Kaplan A, Cook J. Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukaemia. Skinmed 2005; 4: 300-4.
Velez NF, Karia PS, Vartanov BS et al. Association of advanced leukaemic stage and skin cancer tumour stage with poor skin cancer outcomes in patients with chronic lymphocytic leukaemia. JAMA Dermatol 2014; 150: 280-7.
McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003; 88: 74-8.
Agnew KL, Ruchlemer R, Catovsky D et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 1129-35.
Brewer JD, Christenson LJ, Weenig RH, Weaver AL. Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. Dermatol Surg 2010; 36: 368-76.
Ishdorj G, Beiggi S, Nugent Z et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019; 60: 3204-13.
Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. Leuk Lymphoma 2018; 59: 578-82.
Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20: 315-22.
Gualano MR, Osella-Abale S, Marra E et al. Prognostic role in histological regression in primary cutaneous melanoma: a systematic review and meta-analysis. Br J Dermatol 2018; 187: 357-62.
Ribereo S, Galli F, Osella-Abale S et al. Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. J Am Acad Dermatol 2019; 80: 99-105.